China FDA approves Daklinza combos for HCV

Bristol-Myers Squibb Co. (NYSE:BMY) said China FDA approved Daklinza daclatasvir in combination with Sunvepra asunaprevir to treat HCV genotype 1b in patients with or without cirrhosis. The company said it is CFDA's first approval of an all-oral, interferon- and ribavirin-free HCV regimen. BMS markets both drugs in the combo.

CFDA also approved Daklinza in combination with other agents, including Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), for adults with genotype 1-6 infection. Sovaldi is under CFDA review, but is not yet approved in the country...